<DOC>
	<DOCNO>NCT02198248</DOCNO>
	<brief_summary>Previous report suggest conventional immunosuppressant cyclophosphamide could reduce glucocorticoid dose remission induction ANCA-associated vasculitis low remission rate high relapse rate . However report n't include rituximab . B cell depletion therapy rituximab new strategy remission induction ANCA-associated vasculitis . The RAVE RITUXVAS trial ( NEJM 2010 , ) show high-dose glucocorticoid plus rituximab roughly efficacy safety high-dose glucocorticoid plus IV-cyclophosphamide . In addition , recent retrospective observational study report low-dose glucocorticoid plus rituximab lead re-induction severe relapse ANCA-associated vasculitis . Thus , investigator aim investigate whether rituximab reduce glucocorticoid dose induction remission ANCA-associated vasculitis ( show non-inferiority efficacy low-dose high-dose glucocorticoid plus rituximab ) . Participants randomise `` low-dose glucocorticoid plus rituximab '' high-dose glucocorticoid plus rituximab '' group . Primary endpoint proportion remission 6 month , data regard relapse long-term safety collect 24 month . The study design principal coordinating investigator . It include 140 participant 18 hospital Japan . It fund Chiba University Hospital Chiba East Hospital .</brief_summary>
	<brief_title>Low-dose Glucocorticoid Vasculitis Induction Study</brief_title>
	<detailed_description>ANCA ( anti-neutrophil cytoplasmic antibody ) -associated vasculitis characterise small vessel vasculitis presence autoantibody , ANCA . It life-threatening disease renal/respiratory failure . Current standard therapy induction remission ANCA-associated vasculitis combination high-dose glucocorticoid IV-cyclophosphamide . This regimen effective ( remission rate ; 80-90 % ) , often cause various glucocorticoid-related side effect . Especially , infection relate death . Thus new regimen reduce glucocorticoid dose require .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>1 . Provision write informed consent patient surrogate decision maker 2 . Age= &gt; 20 year 3 . New clinical diagnosis ANCAassociated vasculitis ( granulomatosis polyangiitis , microscopic polyangiitis renal limit ANCAassociated vasculitis ) consistent 2012 Chapel Hill consensus definition 4 . Positive test ELISA proteinase 3ANCA myeloperoxidaseANCA 1 . Prior treatment ANCAassociated vasculitis trial entry 2 . ANCAassociated vasculitis relate glomerulonephritis ( eGFR &lt; 15ml/min ) alveolar hemorrhage ( oxygen inhalation &gt; 2L/min ) 3 . Presence another multisystem autoimmune disease 4 . Known infection HIV ; past current history hepatitis B virus hepatitis C virus infection 5 . Desire bear child , pregnancy lactate 6 . History malignancy within past 5 year evidence persistent malignancy 7 . Ongoing recent ( last 1 year ) evidence active tuberculosis 8 . Severe allergy anaphylaxis monoclonal antibody therapy 9 . Any concomitant condition anticipate likely require oral systemic glucocorticoid , immunosuppressant , biologics , plasma exchange IVIg 10 . Any biological B cell deplete agent ( rituximab belimumab ) within past 6 month 11 . Other condition , investigator 's opinion , inappropriate trial entry</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>